Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03896256 · ClinicalTrials.gov registry record · Early Phase 1
Ketamine for Refractory Chronic Migraine: a Pilot Study
A Early Phase 1 study of Migraine Headache With Intractable Migraine, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03896256 is a Early Phase 1 study of Migraine Headache With Intractable Migraine that has completed, run by Thomas Jefferson University. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03896256, a Early Phase 1 study of Migraine Headache With Intractable Migraine, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Ketamine is a drug used for anesthesia but at low doses it is a very effective pain reliever in several chronic conditions. Preliminary studies have shown that ketamine might be effective for patients with refractory chronic migraine, which is a severe type of headache for which patients usually have tried and failed many medications and can cause severe disability to their lives. This study will evaluate ketamine prospectively when given to patients who have "failed" an initial inpatient treatment.
Conditions Studied
Interventions
- DRUG ketamine infusion
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2020-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03896256
The ClinicalTrials.gov registry entry for NCT03896256 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine Headache With Intractable Migraine appearing as the primary indexed condition, and to 1 intervention - of which ketamine infusion is the first listed.
NCT03896256 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03896256 about?
NCT03896256 is a clinical study titled "Ketamine for Refractory Chronic Migraine: a Pilot Study". Ketamine is a drug used for anesthesia but at low doses it is a very effective pain reliever in several chronic conditions. Preliminary studies have shown that ketamine might be effective for patients with refractory chronic migraine, which is a severe type of headache for which patients usually hav...
What is the current status of trial NCT03896256?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-03-22. Estimated completion is 2020-01-01.
What conditions does trial NCT03896256 study?
This clinical trial studies the following conditions: Migraine Headache With Intractable Migraine.
What interventions are being tested in trial NCT03896256?
The interventions under investigation include: ketamine infusion (DRUG).
Who is sponsoring clinical trial NCT03896256?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03896256 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.